SCHEMBL14964989

SCHEMBL14964989

O=C(Cl)c1c(Br)sc(Br)c1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.40
HPGD P15428 2/20 0.36
ALDH1A1 P00352 4/20 0.35
HDAC1 Q13547 1/20 0.35
HTT P42858 2/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.34
GSK3B P49841 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
FABP4 P15090 2/20 0.33
PRNP P04156 1/20 0.33
PPARG P37231 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
GRM6 O15303 1/20 0.33
FABP3 P05413 1/20 0.33
TYMP P19971 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14964825 0.85 ADORA1 (0.42) ADORA1HPGDALDH1A1HDAC1HTT
SCHEMBL14965084 0.74 ALDH1A1 (0.60) HPGDALDH1A1HTTMAPTLMNA
SCHEMBL12361111 0.73 GSK3B (0.48) ALDH1A1GSK3B
SCHEMBL26038502 0.72 ALDH1A1 (0.46) ADORA1HPGDALDH1A1HTTMAPT
SCHEMBL15391391 0.68 ALDH1A1 (0.40) ADORA1ALDH1A1HDAC1HTTMAPT
SCHEMBL28382947 0.67 GAA (0.43) ALDH1A1HTTMAPTLMNAFABP4
SCHEMBL15824265 0.66 ALDH1A1 (0.52) HPGDALDH1A1HTTLMNAFABP4
SCHEMBL28824349 0.66 ALDH1A1 (0.38) ALDH1A1HTTMAPTLMNAFABP4
SCHEMBL10718417 0.65 ALDH1A1 (0.50) HPGDALDH1A1HTTMAPTLMNA
SCHEMBL14225441 0.65 ALDH1A1 (0.37) ADORA1ALDH1A1HTTMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357662-A1 THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2014-12-04 US disclosed
EP-2780344-A1 THIENO [2, 3 - C]PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2014-09-24 EP disclosed
WO-2013072693-A1 THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357662-A1 THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNK3, KCNJ1 ADORA1 486/4885HPGD 2559/4885ALDH1A1 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.